Navigation Links
AbbVie to Present Data on Investigational Anti-Cancer Compounds at American Society of Clinical Oncology Annual Meeting
Date:5/15/2013

I/II Study of Elotuzumab (Elo) plus Lenalidomide/Dexamethasone in Relapsed/Refractory (R/R) Multiple Myeloma: Updated Phase II results and Phase I/II long-term safety; S. Lonial, et al.; Abstract 8542; Poster Discussion Session; June 3, 2013; 1:15 p.m.-5:15 p.m.

ABT-888 (Veliparib)

  • A Phase I Study of Veliparib (ABT-888) in Combination with Carboplatin and Gemcitabine in Subjects with Advanced Solid Tumors; K. M. Bell-McGuinn , et al.; Abstract 2485; Poster Discussion Session; June 3, 2013; 8:00 a.m.-11:45 a.m.

ABT-806

  • A phase I and Biodistribution Study of ABT-806i, an 111 Iindium-Labeled Conjugate of the Tumor-Specific Anti-EGFR Antibody ABT-806; H.K. Gan , et al.; Abstract 2520; Poster Discussion Session; June 4, 2013; 8:00 a.m.-12:30 p.m.

About ABT-199

ABT-199 is a selective inhibitor of B-cell lymphoma-2 (BCL-2) proteins. The B-cell lymphoma 2 gene prevents apoptosis of some cells including lymphocytes, and can be highly expressed in cancers in the lymph nodes, spleen, and other organs of the immune system. As a BH3-mimetic, ABT-199 is designed to block the function of the BCL-2 protein by restoring the communication system that tells cancer cells to self-destruct. Jointly developed by AbbVie and Genentech, the companies are pioneering BCL-2 research with ABT-199, which is currently in Phase 1/1b clinical trials for the treatment of CLL, the most common leukemia in the United States, and several other cancers.

The U.S. Food and Drug Administration (FDA) recently accepted AbbVie's amended clinical trial protocols for studies of ABT-199 in patients with CLL and enrollment for ABT-199 clinical trials in CLL, NHL and multiple myeloma has been re-instated. AbbVie and Genentech expect to move ABT-199 into l
'/>"/>

SOURCE AbbVie
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. AbbVie and Alvine to Collaborate on Investigational Oral Therapy for Celiac Disease
2. AbbVie to Present at Bank of America Merrill Lynch 2013 Health Care Conference
3. AbbVies Investigational HCV Regimen Receives Breakthrough Therapy Designation from the U.S. Food and Drug Administration
4. AbbVie CF Scholarship Application Now Available for Exceptional Undergraduate and Graduate Students with Cystic Fibrosis
5. AbbVie Reports First-Quarter 2013 Financial Results
6. AbbVie to Host First-Quarter Earnings Conference Call
7. Receptos Licenses Anti-Interleukin-13 Antibody from AbbVie for Phase 2 Development in Orphan Disease
8. AbbVie to Present at Barclays Global Health Care Conference
9. AbbVie Issues Inaugural Full-Year Outlook for 2013
10. AbbVie Named to S&P 500 Dividend Aristocrat Index
11. Amgen Highlights Data To Be Presented At American Society of Clinical Oncology Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... Neurelis, Inc. ("Neurelis") today announced an agreement ... held by Biotie to purchase Neurelis, clearing the way ... diazepam) for pediatric and adult epilepsy patients who experience ... Biotie has advanced the development program for NRL-1 and ... work required for NDA submission to the FDA.  Given ...
(Date:7/10/2014)... , 11. Juli 2014  Dilon ... für die molekulare Bildgebung, einschließlich molekularer ... die CE-Zulassung für sein Navigator ® ... Dilon das Produkt jetzt europaweit vertreiben. ... Großteil der europäischen Länder ausgedehnt und ...
(Date:7/10/2014)... July 10, 2014  Breg, Inc., a premier ... launched the FreeRunner™ knee brace with new innovations ... patella mal-tracking return to active lifestyles.  FreeRunner,s patent-pending ... braces, providing support when patients need it most, ... don,t. Patellofemoral issues are the most ...
Breaking Medicine Technology:Neurelis Regains Rights to Intranasal Diazepam Program 2Neurelis Regains Rights to Intranasal Diazepam Program 3Dilon erhält CE-Zulassung für sein Navigator-Gamma-Sondensystem 2Breg Introduces Knee Brace to Help Runners with Patellofemoral Pain Syndrome 2
... DUBLIN, Calif., April 14, 2011 Carl Zeiss ... microscope system at the 79th Annual Meeting of ... Denver, Colo. Based on the breakthrough OPMI® Pentero ... offers innovative new features and customer benefits such ...
... results from the largest multicenter clinical trial for heart ... International Society for Heart & Lung Transplantation (ISHLT) 31st ... show clinical benefit for the use of Everolimus in ... randomized patients at 67 medical centers spanning 5 continents. ...
Cached Medicine Technology:PENTERO 900: Elevating Excellence in Microsurgery to a New Level 2PENTERO 900: Elevating Excellence in Microsurgery to a New Level 3Results From Largest Study of Anti-Rejection Therapy for Heart Transplant Patients Will be Released at ISHLT Meeting 2Results From Largest Study of Anti-Rejection Therapy for Heart Transplant Patients Will be Released at ISHLT Meeting 3Results From Largest Study of Anti-Rejection Therapy for Heart Transplant Patients Will be Released at ISHLT Meeting 4
(Date:7/12/2014)... injuries increase in the summer as people gather around fire ... most vulnerable to these seasonal fire hazards: children. "Young ... by putting their hands on the side of cooking grills," ... Loyola University Medical Center in Maywood, Ill., said in a ... play with fire, you get burned, is true -- ...
(Date:7/12/2014)... New York (PRWEB) July 12, 2014 ... to move forward in U.S. courts, Bernstein Liebhard LLP ... elevated metal ion levels to the failure of metal-on-metal ... 2nd issue of The Journal of Bone & Joint ... received unilateral Articular Surface Replacement prostheses at least twelve ...
(Date:7/12/2014)... (PRWEB) July 12, 2014 Doylestown Hospital ... a variety of men’s health questions. Paddock tackles ... to men, why women live longer than men, and ... Men's Health Made Simple featured on Doylestown Hospital’s ... a hernia at any age. If you notice pain, ...
(Date:7/12/2014)... Praeclarus Press is excited to ... new resource for women in need of lactation support. ... away from their children. Today’s mothers receive very clear ... but often feel unsupported when it comes to balancing ... evidence-based insights, and written by Nancy Mohrbacher, an international ...
(Date:7/12/2014)... 12, 2014 The largest pure occupational ... pleased to announce that it will be opening its ... facility will join four Atlanta-based Nova Medical Centers’ locations. ... 3209 Deans Bridge Road, and will be open from ... , “With Nova’s treatment philosophy of rapid return-to-work and ...
Breaking Medicine News(10 mins):Health News:Burn Injuries More Common in Summer 2Health News:DePuy Pinnacle Hip Lawsuit News: Bernstein Liebhard LLP Notes Release of New Study Tying Elevated Metal Ions to Metal-on-Metal Hip Failure 2Health News:DePuy Pinnacle Hip Lawsuit News: Bernstein Liebhard LLP Notes Release of New Study Tying Elevated Metal Ions to Metal-on-Metal Hip Failure 3Health News:DePuy Pinnacle Hip Lawsuit News: Bernstein Liebhard LLP Notes Release of New Study Tying Elevated Metal Ions to Metal-on-Metal Hip Failure 4Health News:Ivyland Medical Center’s Dr. Brad Paddock Offers Tips for Men’s Health 2Health News:Praeclarus Press Announces the Release of Working and Breastfeeding Made Simple by Nancy Mohrbacher, A Much Needed Resource For Today's Working Mothers 2Health News:Nova Medical Centers To Open New Facility in Augusta, Georgia 2
... , The Authority offers patients consumer ... Advisories for improved patient safety , , ... Authority supports "National Patient Safety Day," Saturday, July 25, which is ... an active role in their healthcare. , , ...
... SHENYANG, China, July 24 /PRNewswire-Asia/ -- Neusoft Medical ... Neusoft Corporation,(600718.SH), officially announced that its newly developed Computed,Tomography(CT) ... by,the FDA recently, and is also marked as the ... multi-slice CT scanner was shipped to its U.S.-based customers,recently, ...
... and phosphate content is common, but labeling is not ... -- Additives used to "enhance" uncooked meat and poultry ... disease, researchers say. , Many fresh meat and poultry ... and flavorings that are not required to be listed ...
... , KENILWORTH, N.J., July 24 Schering-Plough ... settlement, subject to Court approval, to resolve litigation seeking to ... other forms of relief. The consolidated class action lawsuits, ... 2009, were filed in U.S. District Court for the District ...
... , DUBLIN, Ohio, July 24 Cardinal Health ... officer (CIO), effective Aug. 3. , , ... enterprise-wide information technology infrastructure and will work to enhance the ... report to George Barrett, who will become chairman and chief ...
... Dialysis Corporation of America (Nasdaq: DCAI ) announced today ... Wednesday August 5, 2009, after the close of the market. The ... second quarter 2009 earnings release the following morning, Thursday, August 6, ... Those interested in participating in the August 6, 2009 ...
Cached Medicine News:Health News:Pennsylvania Patient Safety Authority Supports 'National Patient Safety Day' 2Health News:Pennsylvania Patient Safety Authority Supports 'National Patient Safety Day' 3Health News:Neusoft Medical's Latest Innovation, NeuViz 16 CT Scanner, Approved by FDA for the U.S. Market 2Health News:Neusoft Medical's Latest Innovation, NeuViz 16 CT Scanner, Approved by FDA for the U.S. Market 3Health News:Fresh-Meat Additives May Be Dangerous for Kidney Patients 2Health News:Schering-Plough Reports Proposed Settlement in Litigation Involving Planned Merger with Merck 2Health News:Cardinal Health Names Patricia Morrison Chief Information Officer 2Health News:Dialysis Corporation of America Announces Second Quarter 2009 Earnings Release Date 2
Introducer Sheath Designed for Vascular Access...
Used to introduce balloon, electrode, closed or non-tapered end and,other catheters....
... The Driver Stent design, ... surpasses the limitations of stainless ... makes possible thinner struts, for ... support. The Driver Coronary Stent ...
The TAXUS Express Paclitaxel-Eluting Coronary Stent System is indicated for improving luminal diameter for the treatment of de novo lesions = 28 mm in length in native coronary arteries = 2.5 to = 3....
Medicine Products: